CD28 and glioma: CD28 blockers abatacept and belatacept have been developed as targeted therapies for transplant rejection and autoimmune disease relative to calcineurin inhibitors and antiproliferative agents (ICIs used in clinical trials for non-glioma cancer immunotherapies are summarized in Supplementary Table S1).